These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 28260425)

  • 1. Optimizing Immunosuppressive Regimens Among Living-Donor Renal Transplant Recipients.
    Bakr MA; Nagib AM; Gheith OA; Hamdy AF; Refaie AF; Donia AF; Neamatalla AH; Eldahshan KF; Denewar AA; Abbas MH; Mostafa AI; Ghoneim MA
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):16-23. PubMed ID: 28260425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
    Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
    Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten-year follow-up of basiliximab induction therapy for live-donor kidney transplant: a prospective randomized controlled study.
    Sheashaa HA; Bakr MA; Rashad RH; Ismail AM; Sobh MA; Ghoneim MA
    Exp Clin Transplant; 2011 Aug; 9(4):247-51. PubMed ID: 21819369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
    Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
    Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
    Bakr MA; Gheith OA; Ismael AM; Baz ME; Shehab El-Dein AB; Ghoneim MA
    Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
    Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
    Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
    Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
    Krämer BK; Krüger B; Mack M; Obed A; Banas B; Paczek L; Schlitt HJ
    Transplant Proc; 2005 May; 37(4):1789-91. PubMed ID: 15919467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants.
    Lentine KL; Schnitzler MA; Xiao H; Brennan DC
    Trials; 2015 Aug; 16():365. PubMed ID: 26285695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.
    Sonmez O; Ozcan SG; Karaca C; Atli Z; Dincer MT; Trabulus S; Seyahi N
    Exp Clin Transplant; 2024 Apr; 22(4):270-276. PubMed ID: 38742317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
    Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up.
    Sheashaa HA; Bakr MA; Fouda MA; El-Dahshan KF; Ismail AM; Sobh MA; Ghoneim MA
    Int Urol Nephrol; 2007; 39(1):317-9. PubMed ID: 17333530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitor-free protocols: risks and benefits.
    Barbari AG; Stephan AG; Masri MA
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.